CLS_US

CLS strengthens its position in the US

During the past year, Clinical Laserthermia System has advanced its position in the urology segment on the US market. A number of agreements have...
Great interest seen in Dicots LIB-01

Great interest in Dicot’s LIB-01

Many interested parties are keeping an eye on the development of LIB-01, Dicot's drug candidate for the treatment of erectile dysfunction, and the interest...
Promore carries out reverse takeover

Promore carries out reverse acquisition and changes its operations

Solna-based Promore Pharma has been in voluntary liquidation since mid-October. The liquidator now seems to have found a solution, which means that the company...
Chordate

Chordate installs system in Germany and launches in the UAE 

Chordate Medical has secured an agreement for the installation of the migraine treatment Ozilia at a private specialist clinic in Germany. This follows from...
Elicera_Legend_Novartis agreement

CAR T deal puts spotlight on Elicera’s technology

Is the hype around CAR T-cell therapies real? A recent licensing agreement struck between Legend Biotech and Novartis to advance novel CAR T candidates...
Curasight accelerates the development of uTREAT

Curasight CEO: “Working on accelerated plan for uTREAT”

Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development. Among other things, the much-anticipated phase II...
Proligt

Prolight’s CEO: ”Proof-of-Performance in whole blood important milestone” 

Prolight Diagnostics has demonstrated Proof-of-Performance in whole blood for its digital test system Psyros. It is already known that the system performs as promised...
Carlos de Sousa, CEO Ultimovacs

Ultimovacs CEO: “Data could put us at the forefront of cancer...

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO...
Toleranzia rapporterar Q2

Scandions CMO: “Our overall survival data are quite impressive”

Scandion Oncologys läkemedelskandidat SCO-101 utvärderas för närvarande i fas II-studien CORIST för behandling av kemoterapiresistent metastaserad tjocktarmscancer. I veckan kunde bolaget meddela positiva data...

Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments”

On Tuesday morning Saniona was able to announce advancements in its Kv7-programme. The company has now concluded the lead optimisation phase and the programme...